---
title: "600351.SH (600351.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600351.SH/news.md"
symbol: "600351.SH"
name: "600351.SH"
parent: "https://longbridge.com/en/quote/600351.SH.md"
datetime: "2026-05-20T20:35:37.757Z"
locales:
  - [en](https://longbridge.com/en/quote/600351.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600351.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600351.SH/news.md)
---

# 600351.SH (600351.SH) — Related News

### [](https://longbridge.com/en/news/286527433.md)
*2026-05-15T07:54:16.000Z*
> The National Healthcare Security Administration issued implementation opinions on reforming and improving the supply gua

### [YABAO PHARM.CORP: Net profit of 320 million yuan in 2025, a year-on-year increase of 31.86%](https://longbridge.com/en/news/283970934.md)
*2026-04-24T09:30:09.000Z*
> YABAO PHARM.CORP announced that it achieved an operating income of 2.24 billion yuan in 2025, a year-on-year decrease of

### [YABAO PHARM.CORP established a new company in Hengqin, Guangdong, with a registered capital of 100 million yuan](https://longbridge.com/en/news/271065429.md)
*2025-12-30T05:33:26.000Z*
> According to the Qichacha APP, recently, YABAO PHARM.CORP was established with a registered capital of 100 million yuan.

### [YABAO PHARM.CORP was established with a registered capital of 100 million](https://longbridge.com/en/news/270823449.md)
*2025-12-26T05:53:12.000Z*
> According to the Tianyancha App, on December 24th, YABAO PHARM.CORP was established, with Ren Wuxian as the legal repres

### [YABAO PHARM.CORP: Sale of 62% equity in subsidiary completed industrial and commercial change registration](https://longbridge.com/en/news/270456795.md)
*2025-12-22T07:36:58.000Z*
> YABAO PHARM.CORP announced that on November 17, 2025, the company held a meeting and approved the proposal to sell 62% o

### [YABAO PHARM.CORP: GLX002 has received the Clinical Trial Approval Notification](https://longbridge.com/en/news/269973052.md)
*2025-12-17T07:41:05.000Z*
> YABAO PHARM.CORP announced that its wholly-owned subsidiary Beijing Yabao Biopharmaceutical Co., Ltd. has obtained appro

### [YABAO PHARM.CORP plans to transfer 62% equity of Taiyuan Pharmaceutical to improve the company's asset operation efficiency](https://longbridge.com/en/news/266181941.md)
*2025-11-17T11:25:23.000Z*
> YABAO PHARM.CORP (600351) announced on the evening of November 17th that it plans to sell 62% of the equity of its holdi

### [YABAO PHARM.CORP plans to sell 62% of its equity in Taiyuan Pharmaceutical to Tongxiang Technology for 87.19 million yuan](https://longbridge.com/en/news/266176430.md)
*2025-11-17T11:07:11.000Z*
> YABAO PHARM.CORP plans to sell 62% of its controlling subsidiary Taiyuan Pharmaceutical for RMB 87.19 million to Tongxia

### [YABAO PHARM.CORP: "Xiao Wei Yuan Su®" has obtained the registration certificate for special medical purpose formula food](https://longbridge.com/en/news/265462398.md)
*2025-11-12T07:49:03.000Z*
> YABAO PHARM.CORP recently obtained the "Special Medical Purpose Formula Food Registration Certificate" issued by the Sta